Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All studies

Velzatinib (IDRX-42, GSK6042981)

StrateGIST 1

GSK · Phase 1 · Active, not recruiting · Enrollment 276

NCT05489237

Catalyst Primary completion. 03.10.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ArmPopulationDoseEstimandComparatorEfficacy
Velzatinib 300 mg tablet (or 400 mg capsule), 2L2L advanced GIST (n = 46)300 mgSingle armn/rmedian progression-free survival: 13.7 months, median follow up 14.7 months; cutoff 12.15.2025objective response rate: 35%, cutoff 12.15.2025
Velzatinib, 1L1L advanced GIST (n = 18)300 mgSingle armn/runconfirmed objective response rate: 61%, median follow up 6.4 months